Comparative analysis of the efficacy of seniprutug (BCD-180) and adalimumab in the treatment of active radiographic axial spondyloarthritis: results of a systematic review and matching-adjusted indirect comparison
Open Access
- 19 April 2024
- journal article
- review article
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 18 (2) , 33-40
Abstract
Objective: to compare the clinical efficacy of seniprutug (BCD-180) and adalimumab (ADA) in the treatment of adults with active radiographic axial spondyloarthritis (r-axSpA).Materials and methods. Based on the results of a previously conducted systematic review, an unanchored matching-adjusted indirect comparison (MAIC) was performed, adjusting for confounding factors. The analysis was based on the results of randomized placebo-controlled clinical trials of seniprutug (BCD-180-2/ELEFTA, NCT05445076) and ADA (ATLAS, NCT00085644) that met the selection criteria. We chose ASAS40 and ASAS20 measurements at week 24 as efficacy outcomes. Initial BASDAI and BASFI indices, proportion of women in the study population, time from disease onset, and baseline C-reactive protein (CRP) levels were considered as confounders.Results and discussion. The MAIC showed a statistically significant advantage in the clinical efficacy of seniprutug (BCD-180) over ADA. When adjusted, the odds ratios (OR) with 95% confidence intervals (CI) for seniprutug (BCD-180)/ADA were 1.86 (1.15; 3.02) and 2.21 (1.34; 3.72) for ASAS40 and ASAS20, respectively, at week 24.Conclusion. The MAIC demonstrated statistically significant superiority of seniprutug (BCD-180) over ADA on the key efficacy endpoints ASAS40 and ASAS20 at week 24 in adults with active r-axSpA. The inclusion of the innovative domestic drug seniprutug into treatment paradigm of active r-axSpA will potentially reduce the socio-economic burden of this disease by providing an affordable, effective and safe therapy while optimizing healthcare costsKeywords
This publication has 17 references indexed in Scilit:
- Targeted depletion of TRBV9+ T cells as immunotherapy in a patient with ankylosing spondylitisNature Medicine, 2023
- Response to: Correspondence on “ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update” by Braun et alAnnals of the Rheumatic Diseases, 2023
- Predicting Probability of Response to Tumor Necrosis Factor Inhibitors for Individual Patients With Ankylosing SpondylitisJAMA Network Open, 2022
- Treatment Failure in Axial Spondyloarthritis: Insights for a Standardized DefinitionAdvances in Therapy, 2022
- Classification vs diagnostic criteria: the challenge of diagnosing axial spondyloarthritisRheumatology, 2020
- Predicting response to anti-TNFα therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-ASRheumatology, 2020
- Clinical, Economic, and Humanistic Burden Associated With Delayed Diagnosis of Axial Spondyloarthritis: A Systematic ReviewRheumatology and Therapy, 2020
- Gender Differences in Axial Spondyloarthritis: Women Are Not So LuckyCurrent Rheumatology Reports, 2018
- Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness ResearchValue in Health, 2012
- Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2006